Risedronate for treating osteoarthritis?
Risedronate is a bisphosphonate type drug which is approved by the FDA for prevention and treatment of osteoporosis. It has been recently evaluated for the treatment of osteoarthritis.
In animal models, some studies have shown that it has decreased pain and slowed the progression of arthritis. However, results in human trials have been less promising. Perhaps further research in this area is required.
"Although risedronate (compared with placebo) did not improve signs or symptoms of OA, nor did it alter progression of OA, a reduction in the level of a marker of cartilage degradation was observed. A sustained clinically relevant improvement in signs and symptoms was observed in all treatment and placebo groups" (Bingham et al, 2006).
Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006 Nov;54(11):3494-507.
Risedronate is a bisphosphonate type drug which is approved by the FDA for prevention and treatment of osteoporosis. It has been recently evaluated for the treatment of osteoarthritis.
In animal models, some studies have shown that it has decreased pain and slowed the progression of arthritis. However, results in human trials have been less promising. Perhaps further research in this area is required.
"Although risedronate (compared with placebo) did not improve signs or symptoms of OA, nor did it alter progression of OA, a reduction in the level of a marker of cartilage degradation was observed. A sustained clinically relevant improvement in signs and symptoms was observed in all treatment and placebo groups" (Bingham et al, 2006).
Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006 Nov;54(11):3494-507.
No comments:
Post a Comment